Table 4.
Clinical Response at Follow-up Visit
| Population | Eravacycline (Clinical Cure/Total) |
Meropenem (Clinical Cure/Total) |
Difference (95% Confidence Interval) |
|---|---|---|---|
| Intent-to-treat | 224/250 (89.6) | 226/250 (90.4) | –0.8 (–6.2, 4.6) |
| Modified intent-to-treat | 224/250 (89.6) | 226/249 (90.8) | –1.2 (–6.5, 4.2) |
| Microbiological intent-to-treat | 170/195 (87.2) | 185/205 (90.2) | –3.1 (–9.5, 3.2) |
| Clinically evaluable | 220/229 (96.1) | 221/231 (95.7) | 0.4 (–3.5, 4.3) |
| Microbiologically evaluable | 168/177 (94.9) | 184/192 (95.8) | –0.9 (–5.7, 3.6) |